ProjectUpdated on 2 August 2025
Liver-in-Cube
About
"Liver-in-Cube”- the world's first 3D-bioprinted biomimetic liver cancer precision theranostic platform, precisely reconstructs the liver cancer microenvironment using patient-derived cells and extracellular matrix. The platform creates personalized “patient avatars” for drug screening that significantly improves the prediction accuracy of drug response rate. This platform overcomes the limitations of empirical animal model and organoid by providing a highly biomimetic, standardized, and high-throughput solution for drug efficacy and pharmacokinetic assessment, shortening R&D cycles and increasing clinical trial success rates. The technology is expanding into a comprehensive precision oncology theranostic system, poised to become the gold standard in cancer standard of care and establish a new paradigm in precision cancer therapy.
Project Location
- China (Hong Kong)
Project Format
- Public-Private Partnership Project
ESG (Environmental, Social, and Governance)
- No
Project Stage
- Operations
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Total Project Value
- 10,000,001 to 25,000,000 USD
Investment Capital Required
- 5,000,001 to 7,500,000 USD
Interested Format of Cooperation
- Open for Negotiation
- R&D Cooperation
Preferred Financing Model
- Open for negotiation
Previous Funding Stage
- Seed & Pre-Series
Main Service(s) Required
- Financial Services
- Professional Services
Financial Services
- Private Equity & Venture Capital
- Risk Management (Financial Services)
Professional Services
- Business Valuation
- Consultancy
- Financial Advisory
- IP Related
- Risk Management
Organisation
Hong Kong, China (Hong Kong)
Similar opportunities
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
- Yes
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- R&D Cooperation
- Seed & Pre-Series
- Financial Services
- Business Valuation
- Corporate Services
- Open for Negotiation
- Open for negotiation
- Professional Services
- Minority Shareholdings
- Institutional Investment
- Feasibility Study Completed
- Market Entry Strategic Analysis
- Private Equity & Venture Capital
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
Shanghai, China
Project
Prohep: Innovative Microbial Therapy for Liver Health and Cancer Prevention
- Yes
- Operations
- Technology
- Seed & Pre-Series
- Medical Technology
- Professional Services
- Public-Private Partnership Project
Terence Hung
Director at Anverio ESG Consulting
Hong Kong, China (Hong Kong)
Project
Single Cell Drug Screening AI Platform
- Yes
- None
- Equity
- Bio-Tech
- Technology
- Private Project
- R&D Cooperation
- Open for negotiation
- Professional Services
- Minority Shareholdings
- 2,500,001 to 5,000,000 USD
- 1,000,001 to 2,500,000 USD
- Feasibility Study Completed
- Public–private partnership / Concession
Marco Suen
Founder & CEO at Provectus Therapeutics Limited
Hong Kong, China (Hong Kong)